当前位置: 首页 > 期刊 > 《中国实用医药》 > 2019年第9期
编号:13387435
观察运动康复疗法对尿毒症肌少症患者的应用效果(3)
http://www.100md.com 2019年3月25日 《中国实用医药》 2019年第9期
     [2] Morley JE, Baumgartner RN, Roubenoff R, et al. Sarcopenia. Journal of Laboratory & Clinical Medicine, 2001, 137(4):231-243.

    [3] Kim JK, Choi SR, Choi MJ, et al. Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. Clin Nutr, 2014, 33(1):64-68.

    [4] Lamarca F, Carrero JJ, Rodrigues JC, et al. Prevalence of sarcopenia in elderly maintenance hemodialysis patients:the impact of different diagnostic criteria. J Nutr Health Aging, 2014, 18(7):710-717.

    [5] Janssen I, Shepard DS, Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soe, 2004, 52 (1):80-85.

    [6] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia:European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing, 2010, 39(4):412-423.

    [7] Fahal IH. Uraemic sarcopenia:aetiology and implications. Nephrol Dial Transplant, 2014, 29(9):1655-1665.

    [8] 吳永耀, 夏敏, 曹盛盛, 等. 血液透析治疗期间个体化运动疗法对尿毒症患者心功能、运动能力的影响及安全性观察. 中国血液净化, 2014, 13(8):580-584.

    [9] 李建英, 黄燕林, 滕艳娟. 运动疗法在尿毒症血液透析患者中的应用进展. 医学理论与实践, 2013, 26(1):25-26.

    [10] 蔡婕. 运动疗法对尿毒症血液透析患者透析充分性的影响体会. 医药前沿, 2016, 6(26):65-66.

    [收稿日期:2018-09-25], 百拇医药(何同林 麦浩添 刘俊华 吴杰蔓 湛雪群)
上一页1 2 3